It all started with the desire to help the youngest in the fight against depression. For this purpose, Calmsie has written an application based on a therapeutic behavioral-cognitive approach, thanks to which children who do not have the opportunity to talk to a psychologist have a chance to take care of their mental well-being. A child between 6 and 12 sits in front of a computer and conducts a scripted conversation with a bot. The whole thing is built into a cartoon. The child chooses various options, and through the plot created by dozens of experts, multiple emotions emerge from the child, which is classically shared during a therapy session. It is how beautiful, empathic, and constructive behavior patterns are built. It is enough for the parent to get a prescription for the application from the doctor, to which he will receive the access code at the pharmacy so that he can use it 2-3 times a day at certain times. Although the project seems controversial, it is the only chance to help children from small towns without psychological support.

The startup’s projects under development include an innovative telemedicine platform, an intelligent system that recommends daily activities to improve the mental health and quality of life of users, and a chatbot that, thanks to the use of NLP, guides you through CBT therapy techniques. All Calmsie functionalities are available through the calmsie.ai platform and soon through Android and iOS applications.

Calmsie also cooperates with research units and universities as part of research and development projects based on innovations on a global scale. The startup is being developed by an interdisciplinary team educated at leading Polish and foreign universities in computer science, mathematics, economics, medicine, and management. The originators, the winners of the IUW Ideas Laboratory, have created a 15-person team experienced in running grants, projects and using new technologies to implement innovative solutions, particularly in medicine, through close cooperation with scientists. No wonder the company operates in Poland and through branches in London (Great Britain) and Miami (USA).